Multiple myeloma is an incurable disease of plasma
cells, which needs some intervention by clinical researchers.
However, there have been recent success in developing such therapy
that can be effective in hematologic malignancies such as chimeric
antigen receptor CAR-T cell therapy, which is expected to be
promising in cancer treatment. However, researchers have found little
success in finding a specific target antigen under CAR T-cell
therapies for treating multiple myeloma. Though, there have been
recent studies that suggest a targeted effect of B-cell maturation
antigen (BCMA) that has been effective in cells with multiple
myelomas. BCMA is a protein, which is selectively expressed by
B-lineage cells that directly work on cells with multiple myelomas.
Researchers are still working to determine the compatibility in
target for CAR-expressing T cells for BCMA. Furthermore, B-cell
maturation antigen (BCMA) is a vital biomarker of the B-cells that is
a promising and newly emerged therapeutic target to treat multiple
myeloma and other hematological malignancies.
Multiple myeloma affected cells are considered to
be having B-cell maturation antigen. This has led to various studies
related to BCMA targeted therapies in the recent past. Multiple
myeloma is the second-most common type of hematological malignancy,
which affects a large population. According to the American Cancer
Society, in 2017, around 30,280 new cases are estimated to be
diagnosed, leading to around 2,600 deaths. Middle-aged men exposed to
any type of radiation or chemicals a past history of monoclonal
gammopathy of undetermined significance (MGUS) are most at risk of
contracting multiple myeloma. Increasing awareness among the research
community and renewed efforts across the globe to effectively treat
cancer and related diseases is expected to provide major traction for
growth of the BCMA targeted therapies market in the foreseeable
future.
Fill the form for an exclusive sample of BCMA
Targeted Therapies market report @
https://www.coherentmarketinsights.com/insight/request-sample/190
BCMA Targeted Therapies Market Taxonomy:
By Product Type
-
CAR-T cells
-
Bispecific Antibodies
-
Antibody Drug Conjugates
By End User
-
Hospitals
-
Cancer Research Institutes
Increase in prevalence of multiple myeloma
globally is expected to support growth of BCMA targeted therapies
market:
Multiple myeloma can be fatal and is linked with
frequent events of re-occurrence of the disorder along various other
serious complications associated with it. The globally widespread
prevalence of the disorder and B-cell malignancies needs specific and
targeted diagnosis and treatments. Hence, there is an immediate
requirement for targeted and effective therapies to provide
appropriate medical care. This in turn is expected to favor growth of
BCMA market in the near future. Multiple myeloma is characterized by
the clonal proliferation of plasma cells in bone marrow, which leads
to bone destruction, renal abnormalities, anemia and hypercalcemia.
The rise in prevalence of multiple myelomas in the population around
the globe is projected to underpin the growth expansion of targeted
therapies in BCMA market in the near future. According to National
Institutes of Health and National Cancer Institute, in 2013, in the
U.S., there were around 96,000 people living with myeloma.
Specificity and targeted effect on cancer
cells is projected to favor growth of the BCMA targeted therapies
market
B cell maturation antigen, is the member of the
tumor necrosis factor receptor group and a type III membrane protein
containing one extracellular cysteine rich domain, which has been
designated as TNFRSF17. The specificity of the therapy to treat the
patients affected from multiple myelomas is projected to be one of
the vital factors favoring growth in adoption of B-Cell Maturation
Antigen targeted therapies in the near future. Furthermore,
collaboration between the existing players in the B-Cell Maturation
Antigen market is expected to be one of the crucial factor in its
growth, this will further expected to enhance the company’s product
portfolio over the forecast period.
Request to view table of content @
https://www.coherentmarketinsights.com/ongoing-insight/toc/190
Key players operating in the BCMA targeted
therapies market include Celgene Corporation, bluebird bio, Poseida
Therapeutics, Inc., Juno Therapeutics, Eureka Therapeutics,
About Us:
Coherent Market Insights is a prominent market
research and consulting firm offering action-ready syndicated
research reports, custom market analysis, consulting services, and
competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
No comments:
Post a Comment